CI
Cigna Corporation
CI's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over CI overall, supported by stronger fundamentals and stronger modeled upside.
CI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Healthy |
CI's balance sheet is currently healthy, and its revenue, profitability and cash flow are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.1x | $296 | — |
| Cheap | 12x | $262 | -12% |
| Current | 13x | $296 | — |
| Fair | 14x | $327 | +10% |
| Expensive | 19x | $439 | +48% |
Historical ranges are pointers, not guarantees.
CI has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for CI, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over CI on the outlook, with more favorable profitability expectations.
CI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $32.62 | +44% |
| Q3 2026 | $22.66 | +0.5% |
| Q2 2026 | $24.17 | +33% |
| Q1 2026 | $23.59 | +31% |
| Q4 2025 | $22.18 | +83% |
| Q3 2025 | $22.55 | +113% |
| Q2 2025 | $18.20 | +43% |
| Q1 2025 | $17.94 | +47% |
| Q4 2024 | $12.12 | -30% |
CI earned $22.66 per share over the past year, about the same as the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CI on earnings, with more consistent year-over-year improvement.
CI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $73.7B | +5.6% |
| Q2 2026 | $71.7B | +6.7% |
| Q1 2026 | $68.5B | +4.6% |
| Q4 2025 | $72.5B | +10% |
| Q3 2025 | $69.7B | +9.5% |
| Q2 2025 | $67.2B | +11% |
| Q1 2025 | $65.5B | +14% |
| Q4 2024 | $65.6B | +28% |
CI's revenue has grown year over year every quarter since late 2020: $73.7B last quarter, up 5.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.3% | -0.5 points |
| Q2 2026 | 3.7% | +0.3 points |
| Q1 2026 | 3.4% | +0.4 points |
| Q4 2025 | 3.2% | -0.1 points |
| Q3 2025 | 3.7% | -0.3 points |
| Q2 2025 | 3.4% | -0.6 points |
| Q1 2025 | 3% | -0.9 points |
| Q4 2024 | 3.3% | -0.7 points |
CI's operating margin was 3.3% last quarter, about level with the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CI on profitability, with a higher operating margin.
CI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6B | -25% |
| Q2 2026 | -$421M | +$1.5B |
| Q1 2026 | $1.1B | -41% |
| Q4 2025 | $6.1B | +18% |
| Q3 2025 | $3.4B | +7330% |
| Q2 2025 | -$1.9B | -812% |
| Q1 2025 | $1.9B | -60% |
| Q4 2024 | $5.2B | +255% |
CI generated $9.4B in free cash flow over the past year, up 8.8% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CI on cash flow, with more consistent year-over-year improvement.
CI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -174K shares |
| 1 year | -1.4% | -3.7M shares |
| 3 years | -11% | -33.3M shares |
| 5 years | -22% | -73.8M shares |
| Available history | -31% | -116M shares |
CI has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $251M |
| Q2 2026 | $280M |
| Q1 2026 | — |
| Q4 2025 | $1B |
| Q3 2025 | — |
| Q2 2025 | $1.1B |
| Q1 2025 | $1.5B |
| Q4 2024 | $2B |
CI spent $1.5B buying back its own shares over the past year, down 67% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Healthy |
| Q2 2026 | 2.0x | Moderate |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 2.0x | Moderate |
CI's net debt is about 2.0 years of its operating earnings (EBITDA), down from 2.4 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over CI on leverage, with a lower net debt burden relative to earnings.
CI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.0 | Neutral |
| Stochastic | 60.8 | Neutral |
CI's weekly RSI is 56 (neutral) and its Stochastic is 61 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CI PE vs Healthcare Sector
| Metric | CI | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 49% below |
| PE % | 40 | 29 | 11 pts above |
CI has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $290.3 | 2.1% above |
| 20 week MA | $285.7 | 3.7% above |
| 50 week MA | $281.4 | 5.3% above |
| 100 week MA | $291.1 | 1.8% above |
| 200 week MA | $299.9 | 1.2% below |
CI has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 1.2% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CI on trend strength, trading above more of its moving averages.
CI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $204.0 | $198.8 | -2.5% |
| 2021 | $198.8 | $225.9 | +14% |
| 2022 | $225.9 | $334.3 | +48% |
| 2023 | $334.3 | $299.5 | -10% |
| 2024 | $299.5 | $278.7 | -6.9% |
| 2025 | $278.7 | $276.5 | -0.8% |
| 2026 YTD | $276.5 | $296.3 | +7.1% |
CI has finished three years in a row lower, and it's up 7.1% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CI on returns for 2026, with the stronger performance.